It may not look like one, but the Implantable Artificial Kidney device has been designed to function in the same way as a human kidney. By extracting waste and keeping nutrients needed by the body, it could one day help those with chronic renal failure.
According to the Implantable Artificial Kidney Corporation, the organization developing and testing the device, it uses special filters, osmosis/diffusion and reverse osmosis to separate waste material and water.
In the average healthy adult, kidneys process around 45 gallons each day in order to filter out nearly 2 quarts of waste product and extra water in the urine.
Since the kidney's main function is to remove excess minerals and wastes, such as creatinine and urea, patients who suffer from chronic renal failure (CRF) need dialysis to help rid the body of these wastes or they need to undergo transplantation.
However, unlike transplantation, which risks rejection from the body, the Artificial Kidney device has been designed to not be rejected by the body, effectively doing away with post-operative immunosuppressant drugs and the frequent monitoring that a kidney transplant patient requires for the rest of his or her life.
The Implantable Artificial Kidney, shown here without filters and covers, works like a human kidney by removing excess minerals and wastes from the body.
Source: Implantable Artificial Kidney Corporation
The device, which can either be implanted or worn outside the body, will create urine immediately, unlike a human implanted kidney, which can sometimes take 2 weeks or longer to begin working.
According to the company, the device's design is the only one of its kind - it is small and is built using plastic materials described as being "medically safe."
Roland G. Ludlow, CEO of the Implantable Artificial Kidney Corporation, says:
"The simplicity of design and its small size make it unique. Past in-house tests separated the materials effectively. We are making great progress, and we are extremely excited about its potential."
He says that recent upgrades have been undertaken, and once complete, the device will be ready for a full test by a third party laboratory.
Chronic renal failure in the US
According to the Centers for Disease Control and Prevention (CDC) National Center for Health Statistics, there were 50,476 kidney failure-related deaths in 2010, making mortality due to kidney failure number eight on the cause of death list in the US.
Additionally, in 2011, there were 4.4 million noninstitutionalized adults who were diagnosed with kidney disease, which is nearly 2% of adults.
Not only are kidney transplants tricky because of the risks involved with the body rejecting the organ, but also finding a suitable donor is quite difficult, and many people must continue dialysis while they sit on a waiting list for transplantation.
Once their device is out of the laboratory testing phase, the organization plans to implant the artificial kidney into pigs in less than a year, as their circulatory system is similar to a human's. They note that they would prefer to do this at a state university that has a medical and agricultural facility.
Ludlow told Medical News Today:
"Our upgraded prototype is being fitted with new filters as we speak. We will have some in-house testing completed within two weeks. If they are successful, and nothing more needs to be done to the device, we will have an ISO accredited lab test. If that goes well, we will begin the first implant operation on a pig. We feel that we are less than a year from this point."
The goal is to design the device to last for over 10 years so that it does not require any maintenance during its lifespan.
Medical News Today recently reported that a smartphone device can test for kidney damage.
Update from the Implantable Artificial Kidney Corporation added on February 14th, 2014:
On February 12th, 2014 Charles E. Jennings, inventor, chief scientist, and president of the Implantable Artificial Kidney Corporation (IAKC) passed away after being hospitalized following by-pass surgery. His condition worsened during recovery when he suffered a severe stroke that left him unconscious and eventually led to his death.
"Mr. Jennings was a gifted individual. He was highly intelligent, a humanitarian, a visionary and a dear friend. We are deeply saddened by his loss. We are now the keepers of the flame, and we will see to it that his work is completed", Said IAKC's CEO Roland G. Ludlow.
Though the news was sad, unexpected, and shocking, the board of directors of the IAKC says that enough of the science is completed to continue their project. They plan to carry on the unprecedented work begun by Mr. Jennings and finish all phases of the project. The project is in the middle phase of research and development. The company is finishing testing prototypes, and expects to reach the animal testing phase in less than one year.